Product Name

Carisoprodol

Name: Carisoprodol - LGM Pharma
SKU: 78-44-4

CAS Number

78-44-4

LGM Pharma is an API distributor. LGM Pharma supplies APIs as per CGMP with DMF support, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, or pharmacies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:

Carisoprodol

CAS Number:

78-44-4

Indication:

For the relief of discomfort associated with acute, painful, musculoskeletal conditions.

Mode of Action:

Carisoprodol is a central nervous system depressant that acts as a sedative and skeletal muscle relaxant. Rather than acting directly on skeletal muscle, carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. Its exact mechanism of action is not yet known.

Pharmacodynamics:

Carisoprodol is used as a skeletal muscle relaxant. One of its metabolites, meprobamate, is available as an anxiolytic agent.

Metabolism:

Hepatic. Metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19.

Toxicity:

Symptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives

IUPAC:

2-methyl-2-({[(propan-2-yl)carbamoyl]oxy}methyl)pentyl carbamate

ATC:

M03BA02

PubChem:

2576

DrugBank:

DB00395 (APRD00417)

Formula:

C₃₂H₄₄O₇

Molecular Mass:

260.33

Synonyms:

Carisoprodate Carisoprodatum Isomeprobamate Isoprotane Isoprothane

SMILES:

CCCC(C)(COC(N)=O)COC(=O)NC(C)C

InChi:

OFZCIYFFPZCNJE-UHFFFAOYSA-N

General Reference:

Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004 Sep;26(9):1355-67. Pubmed
Chou R, Peterson K, Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. Pubmed
Littrell RA, Hayes LR, Stillner V: Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J. 1993 Jul;86(7):753-6. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210.

Ask us about this product

API’s From Quality Manufacturers:

Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
Premium quality GMP certified and fully accredited API manufacturing plants
Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
Regulatory and technical assistance towards any submission type based on specific customer requirements

Carisoprodol

78-44-4

Ask us about this product

API’s From Quality Manufacturers:

Find an API Product